CCL24, CXCL9 and CXCL10 are increased in synovial fluid in patients with juvenile idiopathic arthritis requiring advanced treatment
An erratum to this article was published (Rheumatology (Oxford), 1 Mar 2025 ↗)
Authors' conclusion
In patients with oligoarticular JIA, regardless of disease onset and progression, the consistent elevation of any or all three markers, the CCL24, CXCL9 and CXCL10 in SFs was associated with the future use of advanced therapy, which could be reflective of disease severity.
Study context
- Population
- Patients with persistent and extended oligoarticular JIA
- Exposure
- Patients who eventually received advanced medications vs those who did not
- Outcome
- SF CCL24, CXCL9 and CXCL10 expression
Methodological detailsserial synovial fluid samples, protein antibody arrays and Luminex assays
- Serial synovial fluid samples
- Protein antibody arrays and Luminex assays
Main finding
As reported in the abstract
- CCL24, CXCL9 and CXCL10 expression significantly higher in patients who eventually required advanced treatment than in those who did not
- CCL24 and CXCL9 consistently elevated in paired samples of those who later received advanced medications
Observational data: associations, not effects.
Further findings
Persistent oligoarticular JIA: change over time
- CXCL10 remained elevated over time in those requiring advanced treatment
- CCL24 decreased in those not requiring advanced treatment
Extended oligoarticular JIA: change over time
- CCL24 and CXCL10 increased significantly over time in those who ultimately required advanced treatment
Original publication
CCL24, CXCL9 and CXCL10 are increased in synovial fluid in patients with juvenile idiopathic arthritis requiring advanced treatment. Rheumatology (Oxford). Published 7 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →